Big Cardio Medtechs Are Moving ESG Agenda To Center Stage In 2022
Executive Summary
In Vivo outlines major trends shaping the top 15 cardiovascular device companies included in the latest Medtech 100 rankings. They include a growing need to reach underserved patient populations, ongoing staffing and other challenges created by the COVID-19 pandemic, and reimbursement obstacles.
You may also be interested in...
Abbott Focuses On Improving Early Diagnosis Of Vascular Disease To Improve Outcomes
Nick West, chief medical officer for Abbott’s vascular business talked to Medtech Insight about Abbott’s efforts to improve the assessment and treatment of vascular disease long before patients need an intervention.
Minute Insight: Big Medtechs Usually Do Well During High Inflation, But Not in 2021
A new analysis from Wells Fargo found that the big medtech stocks typically perform at least as well as the overall market when inflationary expectations are high, but 2021 defied that trend.
Minute Insight: Philips Continues Building Monitoring Business By Acquiring Cardiologs
Paris-based Cardiologs is developing machine learning software to analyze electrocardiogram waveforms to detect arrhythmias.